plenti pipelin news ahead
look set year signific pipelin news year pfizer
like gain two major label expans import growth driver
xeljanz ulcer coliti xtandi non-metastat prostat cancer
gain two new drug approv oncolog talazoparib breast cancer
lorlatinib lung cancer get first result phase trial three
import pipelin drug tafamidi cardiomyopathi tanezumab
arthrit back pain rivipansel sickl cell pain crise
therefor import year move establish wave growth
driver secur solid growth beyond heavi loss-of-exclus
forecast sale grow per annum
acceler new growth driver come
updat model us tax reform also take opportun
updat model reflect posit impact us tax reform pfizer
core tax rate drop
medium-term sale rise pipelin contribut sale forecast
unchang forecast rise
build stronger contribut phase pipelin across
rang phase asset discuss import
year pipelin develop
earn mid-high singl digit combin higher
medium-term sale lower corpor tax rate drive non-gaap ep
upgrad see non-gaap ep growth per
annum nudg previou forecast per annum
price target move hold maintain dcf-deriv price target
climb impli upsid current
level pfizer multipl discount sector
look touch overdon given compani close-to-sector earn
growth retain hold recommend see
greater upsid elsewher sector
chang made note
hold chang
perform rel
compani base us
global biopharmaceut
profit loss summari
growth margin
face sale headwind
patent expiri drug lyrica viagra enbrel
howev key growth driver ibranc eliqui xeljanz
xtandi fill gap next five year
pfizer pipelin hold promis recent year
year see import phase read out perhap data
pain drug tanezumab could interest side-effect
profil emerg manag
aggreg see low single-digit sale growth mid-singl
under-valued growth dramat rel
valuat base dcf model
chang net debt
average cost debt
risk invest thesi
pin hope new wave pipelin project late
stage develop posit data eg tanezumab pain could
drive earn upgrad without risk attach
potenti boost busi and/or
releas valu dispos eg consum major
activ could significantli chang busi outlook
enbrel ex us canada
peri-lo product inc lyrica eh viagra eh
sale
sell inform admin
 revenu
 revenu
amort intang asset
net incom attribut
net incom attribut
net incom attribut
net incom attribut
weight averag number share dilut million
cash equival
properti plant equip net
short term borrow inc current portion long-term debt
accru compens relat item
total liabil equiti
total liabil equiti
total liabil equiti
total liabil equiti
net incom alloc non-control interest
depreci amort
net cash provid oper activ
net cash provid oper activ
net cash provid oper activ
net cash provid oper activ
purchas properti plant equip
acquisit busi net cash acquir
net cash use invest activ
net cash use invest activ
net cash use invest activ
net cash use invest activ
purchas common stock
net cash use financ activ
net cash use financ activ
net cash use financ activ
net cash use financ activ
fx effect cash cash equival
net cash cash equival increas
cash equival begin year
cash equival end year
cash equival end year
cash equival end year
cash equival end year
pleas note use research report subject condit restrict set forth gener inv
pleas note use research report subject condit restrict set forth gener invest
pleas note use research report subject condit restrict set forth gener inv
pleas note use research report subject condit restrict set forth gener inv
disclosur legal disclaim end document
